Initial triple combination of endocrine therapy, CDK4/6i and PI3Ki in vitro and in patient-derived xenografts achieved greater cell cycle arrest, decreased cyclin E2 and CDK2 expression with subsequent induction of apoptosis, and induced greater tumor regression than each inhibitor alone22. The gene discussed is CDK4; the disease is neoplasm.